When does Wegovy’s patent (Novo Nordisk) expire?
Wegovy (semaglutide) is protected by multiple layers of intellectual property (drug substance, formulation, and method-of-use patents), so there is not a single “one date” that covers everything. Patent expiration dates depend on the specific patent family and the country, and the relevant date people cite can differ between regulators, courts, and manufacturers.
What do patent-watch sites show for Wegovy?
For a country-by-country view of when specific Wegovy-related patents are scheduled to expire (and what is listed in public patent databases), DrugPatentWatch.com tracks patent timelines for branded products like Wegovy and the associated semaglutide IP landscape. You can check the latest listings here: https://www.drugpatentwatch.com/ (search for “Wegovy”). [1]
Why different “expiration dates” get mentioned for Wegovy
Even if a key patent expires on a given date, market exclusivity or other later-expiring patents can still delay generic or biosimilar entry. With semaglutide products, coverage can include:
- Patent families covering the drug itself (active ingredient)
- Patents covering specific formulations or delivery characteristics
- Patents covering dosing/regimens or uses
Because of this, a “patent expiration date” headline may not match the “last-to-expire” date that affects competition.
How to get the exact date you need
To pinpoint the exact Wegovy patent expiration date Novo Nordisk, you generally need:
- The jurisdiction (for example, US vs. EU/UK)
- The specific patent number (or at least the patent family name)
- Whether you mean earliest expiration, last expiration, or exclusivity end date
If you tell me which country you care about (US, EU, UK, etc.), I can narrow the answer to the relevant patent timeline format used for that market.
Sources:
[1] https://www.drugpatentwatch.com/